Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2017 June;108(3) > Minerva Medica 2017 June;108(3):239-54

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

REVIEW  


Minerva Medica 2017 June;108(3):239-54

DOI: 10.23736/S0026-4806.17.05050-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Biosimilars in inflammatory bowel disease

Carla J. GARGALLO 1, 2, Alberto LUÉ 1, 2, Fernando GOMOLLÓN 1, 2, 3, 4

1 Department of Gastroenterology, “Lozano Blesa” Clinical University Hospital, Zaragoza, Spain; 2 IIS Aragón, Zaragoza, Spain; 3 University of Zaragoza, Zaragoza, Spain; 4 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain


PDF  


The introduction of biologic therapies has revolutionized the treatment of inflammatory bowel disease (IBD) and has significantly improved the disease course and outcomes for many patients. Biologics are the main drivers of cost in many IBD units and biosimilars, although are not better than originators, are usually cheaper and thus can increase the availability of this type of therapy. Biosimilar are highly similar to innovator but, due to the complex structures of innovators and the variability inherent in the manufacturing process, they are no identical. This fact cause concerns with respect to the efficacy and safety in medical community, especially in the medical indications in which no specific clinical trials with biosimilars have been performed as IBD. Nowadays, two biosimilars to infliximab, CT-P13 and SB2, has been approved by European Medicines Agency in all the indications of the reference product. To date, the available evidence suggests that switch from reference medicinal product (infliximab) to the biosimilar (CT-P13 or SB2) is feasible since published studies have not observed significantly difference in terms of efficacy, immunogenicity and safety. However, the experts agreed that by now there is not sufficient evidence to consider infliximab biosimilars interchangeable with the originator compound. In this manuscript, we will review the processes involved in the manufacturing and regulatory approval of biosimilars and examine the evidence presently available on approved biosimilars in Europe for IBD.


KEY WORDS: Inflammatory bowel diseases - Crohn disease - Colitis, ulcerative - Biosimilar pharmaceuticals - CT-P13 - Infliximab

top of page

Publication History

Issue published online: March 8, 2017
Article first published online: February 7, 2017

Cite this article as

Gargallo CJ, Lué A, Gomollón F. Biosimilars in inflammatory bowel disease. Minerva Med 2017;108:239-54. DOI: 10.23736/S0026-4806.17.05050-9

Corresponding author e-mail

fgomollon@gmail.com